2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2864

Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Abstract Number: 2865

The Utility and Limitations of Serum C-Reactive Protein in Appraising Synovial Inflammation
Abstract Number: 2866

Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Abstract Number: 2867

CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Abstract Number: 2868

Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
Abstract Number: 2869

Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Abstract Number: 2870

Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Abstract Number: 2871

Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 2872

Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity
Abstract Number: 2873

DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Abstract Number: 2874

Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome
Abstract Number: 2875

Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets
Abstract Number: 2876

Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Abstract Number: 2877

Premature Senescence of Naive CD4+ T-Cells in Primary Sjogren’s Syndrome
Abstract Number: 2878

Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].